34 results about "Fumaric Acid Esters" patented technology

A pharmaceutical controlled release composition comprising one or more fumaric acid esters.

The invention features a kit. The kit includes: (i) a first unit dosage form consisting essentially of about 120 mg of dimethylfumarate and one or more pharmaceutically acceptable excipients, wherein the dimethylfumarate is formulated for delayed release; and (ii) a second unit dosage form consisting essentially of about 240 mg of dimethylfumarate and one or more pharmaceutically acceptable excipients, wherein the dimethylfumarate is formulated for delayed release.

A coating composition is provided. The composition comprises as component I, a) a polyaspartic acid ester comprising the reaction product of one more diamines, one or more difunctional acrylate-containing compounds and one or more maleic / fumaric acid esters; b) at least one moisture scavenger; c) at least one deaerator; d) at least one plasticizer; and e) optionally additives; and as component II, one or more polyisocyanates. Methods of making and applying the composition to a substrate are also provided. The coating is particularly suitable for use as a gel coat.

The invention relates to a combination therapy for the prevention and / or treatment of immune-mediated chronic inflammatory and autoimmune diseases comprising a combination of one or more C3-C8 carboxylic acids, physiologically acceptable salts and / or esters thereof, and one or more fumaric acid esters and / or salts thereof. The combination being particularly useful in the treatment of psoriasis and multiple sclerosis.

Methods of using one or more fumaric acid esters or pharmacologically active salts, derivatives, analogues, or prodrugs thereof to increase expression of fetal hemoglobin (HbF) are disclosed. The methods typically include administering to a subject an effective amount of one or more fumaric acid esters optionally in combination or alternation with hydroxyurea to induce HbF expression in the subject in an effective amount to reduce one or more symptoms of a sickle cell disorder, a hemoglobinopathy, or a beta-thalassemia, or to compensate for a genetic mutation is the human beta-globin gene (HBB) or an expression control sequence thereof. Pharmaceutical dosage units and dosage regimes for use in the disclosed methods are also provided.

The present invention relates to novel radiation-curing powder coating binders containing maleic and / or fumaric acid esters and one or more amorphous or partially crystalline resins containing at least one group that reacts with ethylenically unsaturated compounds under the action of actinic radiation to form a polymer. The binders have a glass transition temperature ranging from 30 to 90° C. The binders can be used as a constituent in coating compositions.

The invention belongs to the technical field of chemical engineering, and in particular relates to a method for synthesizing beta-ester group-gamma-butyrolactam and gamma-ester group-delta-valerolactam. The method comprises the following steps: by taking ZnEt2 as an alkylation reagent, performing selective alkylation on fumaric acid ester, itaconic acid ester and methylic glutarate at near room-temperature, and performing Mannich addition on imine, and performing a cyclization reaction. The method provided by the invention is common in reaction raw material and low in price, a transition metal catalyst is not needed, one-pot method synthesis is achieved in a same reaction container through serial reactions, separation process and product loss can be reduced, the method is simple and convenient to operate, efficient in process and mild in condition, and the reactions can be implemented at normal temperature or near room-temperature.